A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.

Celgene

Status: Completed

Conditions: Pancreatic Cancer

Treatments: Drug: ABI-007

Study type: Observational

Funder types: Industry

Identifiers

NCT02021500

ABI-007-PANC-CA046C

Details and patient eligibility

About

A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.

Full description

A study to collect survival status of CA046 subjects who were know to be alive at the last report of vital status for CA046 - approximate timeframe - end of March, 2013. Once consent is given, on a quarterly basis, information on status will be collected to include:

• Vital Status
• Date of disease progression
• Subsequent anticancer therapy for pancreatic adenocarcinoma

Enrollment: 40 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have been enrolled in the CA046 study Must have been living at the time of the last survival follow-up (approximate timeframe - end of March, 2013) Must understand and be able to give informed consent (if a subject is deceased, proper legal consent (ie, next of kin, legal representative) will be obtained prior to collection of data)

Exclusion criteria

• Consent refused for any reason

Trial design

40 participants in 1 patient group

Patients previously enrolled in study CA046

Description:

No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)

Treatment:

Drug: ABI-007